Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial

被引：0
|
作者：
Jun Guo
Jie Jin
Mototsugu Oya
Hirotsugu Uemura
Shunji Takahashi
Katsunori Tatsugami
Sun Young Rha
Jae-Lyun Lee
Jinsoo Chung
Ho Yeong Lim
Hsi Chin Wu
Yen Hwa Chang
Arun Azad
Ian D. Davis
Marlene J. Carrasco-Alfonso
Bhupinder Nanua
Jackie Han
Qasim Ahmad
Robert Motzer
机构：
[1] Peking University Cancer Hospital and Institute,Department Urology and Melanoma
[2] Peking University First Hospital,Department of Urology
[3] Keio University School of Medicine,Department of Urology
[4] Kindai University Faculty of Medicine,Department of Urology
[5] Cancer Institute Hospital,Department of Medical Oncology
[6] Japanese Foundation for Cancer Research,Department of Urology, Graduate School of Medical Sciences
[7] Kyushu University,Department of Oncology and Internal Medicine, Asan Medical Center
[8] Yonsei Cancer Center,Department of Urology
[9] Yonsei University College of Medicine,Division of Hematology
[10] University of Ulsan College of Medicine,Oncology
[11] Center for Prostate Cancer,Department of Urology
[12] National Cancer Center,Division of Urology, Department of Surgery
[13] Samsung Medical Center,Department of Medicine
[14] Sungkyunkwan University,Department of Medicine
[15] China Medical University Hospital,undefined
[16] Taipei Veterans General Hospital,undefined
[17] Monash University,undefined
[18] Monash University,undefined
[19] Eastern Health Clinical School,undefined
[20] Novartis Pharmaceuticals Corporation,undefined
[21] Novartis Pharmaceuticals Corporation,undefined
[22] Genitourinary Oncology Service,undefined
[23] Memorial Sloan-Kettering Cancer Center,undefined
来源：
Journal of Hematology & Oncology | / 11卷
关键词：
Renal cell carcinoma; Pazopanib; Sunitinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] Safety of pazopanib and sunitinib in treatment-naive patients with metastatic renal cell carcinoma: Asian versus non-Asian subgroup analysis of the COMPARZ trial
    Guo, Jun
    Jin, Jie
    Oya, Mototsugu
    Uemura, Hirotsugu
    Takahashi, Shunji
    Tatsugami, Katsunori
    Rha, Sun Young
    Lee, Jae-Lyun
    Chung, Jinsoo
    Lim, Ho Yeong
    Wu, Hsi Chin
    Chang, Yen Hwa
    Azad, Arun
    Davis, Ian D.
    Carrasco-Alfonso, Marlene J.
    Nanua, Bhupinder
    Han, Jackie
    Ahmad, Qasim
    Motzer, Robert
    JOURNAL OF HEMATOLOGY & ONCOLOGY, 2018, 11
  • [2] Comparison of PFS and safety for Asian compared to North American and European populations in the phase III trial of pazopanib versus sunitinib in patients with treatment-naive RCC (COMPARZ)
    Guo, Jun
    Jin, Jie
    Huang, Yiran
    Wang, Jin-Wan
    Lim, Ho Yeong
    Uemura, Hirotsugu
    Rha, Sun Young
    Wu, Hsi Chin
    Crescenzo, Rocco
    Deen, Keith C.
    McCann, Lauren
    Motzer, Robert John
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [3] Adjuvant axitinib in Asian vs non-Asian patients with metastatic renal cell carcinoma (mRCC): ATLAS trial subgroup analysis
    Ng, C. F.
    Kwon, T. G.
    Eto, M.
    Miyake, H.
    Seo, S. I.
    Byun, S-S.
    Lee, J. L.
    Rosbrook, B.
    Grande, E.
    Gross-Goupil, M.
    Quinn, D. I.
    ANNALS OF ONCOLOGY, 2019, 30
  • [4] Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies
    Xinan Sheng
    Jie Jin
    Zhisong He
    Yiran Huang
    Aiping Zhou
    Jinwan Wang
    Xiubao Ren
    Dingwei Ye
    Xu Zhang
    Shukui Qin
    Fangjian Zhou
    Binhui Wang
    Jun Guo
    BMC Cancer, 20
  • [5] Pazopanib versus sunitinib in Chinese patients with locally advanced or metastatic renal cell carcinoma: pooled subgroup analysis from the randomized, COMPARZ studies
    Sheng, Xinan
    Jin, Jie
    He, Zhisong
    Huang, Yiran
    Zhou, Aiping
    Wang, Jinwan
    Ren, Xiubao
    Ye, Dingwei
    Zhang, Xu
    Qin, Shukui
    Zhou, Fangjian
    Wang, Binhui
    Guo, Jun
    BMC CANCER, 2020, 20 (01)
  • [6] Efficacy and safety of pazopanib (PAZ) versus sunitinib (SUN) in patients (pts) with locally advanced or metastatic renal cell carcinoma (RCC): A pooled China subgroup analysis from COMPARZ studies
    Sheng, Xinan
    Jin, Jie
    He, Zhisong
    Huang, Yiran
    Zhou, Ai-Ping
    Wang, Jinwan
    Ren, Xiu-Bao
    Ye, Dingwei
    Zhang, Xu
    Qin, Shukui
    Zhou, Fang-Jian
    Guo, Yanfang
    Guo, Jun
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [7] An Asian subpopulation analysis of the safety and efficacy of sunitinib in metastatic renal cell carcinoma
    Lee, S.
    Chung, H. C.
    Mainwaring, P.
    Ng, C.
    Chang, J. W. C.
    Kwong, P.
    Li, R. K.
    Sriuranpong, V.
    Toh, C. K.
    Lowenthal, S. Pitman
    EJC SUPPLEMENTS, 2009, 7 (02): : 428 - 428
  • [8] Comparative evaluation of safety and efficacy of alternate schedule of sunitinib in non-Asian and Asian patient population for treatment of metastatic renal cell cancer: A meta-analysis
    Kapse, P.
    Singh, M.
    Alam, M.
    ANNALS OF ONCOLOGY, 2017, 28
  • [9] Comparative Evaluation of Safety and Efficacy of Alternate Schedule (AS) of Sunitinib in Asian and Non-Asian Patient Population for the Treatment of Metastatic Renal Cell Cancer (mRCC): A Meta-Analysis
    Joshi, Amit
    Patel, Ishan
    Kapse, Pratiksha
    Singh, Manmohan
    KIDNEY CANCER, 2022, 6 (01) : 37 - 51
  • [10] Sunitinib in metastatic renal cell carcinoma: An ethnic Asian subpopulation analysis for safety and efficacy
    Lee, Se-Hoon
    Bang, Yung-Jue
    Mainwaring, Paul
    Ng, Christina
    Chang, John W-C
    Kwong, Philip
    Li, Rubi K.
    Sriuranpong, Virote
    Toh, Chee-Keong
    Yuan, Jinyu
    Pitman Lowenthal, Susan
    Chung, Hyun C.
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2014, 10 (03) : 237 - 245
12345